Combined Lung and Bone Marrow Transplantation for Treating Lung and Bone Marrow Failure in Adults

What this Trial Is About

This research aims to evaluate the safety and effectiveness of performing a lung transplantation followed by a partially matched, CD3CD19 depleted bone marrow transplantation from the same cadaveric donor in patients with bone marrow failure and end-stage lung disease. The study focuses on individuals with idiopathic pulmonary fibrosis and related conditions who cannot undergo standard lung transplantation. The goal is to restore lung function before bone marrow transplantation and then to recover blood cell function after the bone marrow transplant. Participants will receive a lung transplant using standard induction treatments tailored to their health status, possibly including rituximab and tacrolimus for immune system management. At least eight weeks after the lung transplant, they will undergo bone marrow transplantation with marrow processed to remove specific immune cells. The bone marrow is recovered from the same donor as the lung and prepared using specialized devices to reduce immune complications. During the study, participants will be closely monitored for up to two years after stem cell transplantation. Researchers will assess survival, success of bone marrow engraftment, lung function, immune cell presence, blood cell recovery without growth factors, and complications related to both lung and bone marrow transplants. The study will also evaluate long-term immune tolerance, the ability to reduce or stop immunosuppressive drugs, and the occurrence of transplant rejection or graft-versus-host disease.

Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure